Disease-modifying Therapy
Tuesday, October 26, 2021: 5:00 PM-7:00 PM
Exhibit Hall (Rosen Shingle Creek)
Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis
Xavier Montalban, MD, PhD, Vall d'Hebron University Hospital;
Douglas L. Arnold, MD, McGill University;
Martin S Weber, MD, Universitie Göttingen;
Ivan Staikov, MD, PhD, Acibadem City Clinic Tokuda Hospital;
Karolina Piasecka-Stryczynska, PhD, Poznan University of Medical Sciences;
Emily C. Martin, PhD, EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany;
Matthew Mandel, MD, EMD Serono Research & Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt, Germany);
Fernando Dangond, MD, MBA, EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany;
Jerry S Wolinsky, MD, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth)
Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Amy Perrin Ross, APN, MSN, CNRN, MSCN, Loyola University Chicago;
Thomas Berger, MD, MSc, Department of Neurology, Medical University of Vienna;
Robert A Bermel, MD, Mellen Center for MS, Cleveland Clinic;
Bruno Brochet, MD, University of Bordeaux;
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC, University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute;
Trygve Holmøy, MD, PhD, Department of Neurology, Akershus University Hospital, Institute of Clinical Medicine, University of Oslo;
Rana Karabudak, Prof., MD, Hacettepe University Faculty of Medicine;
Joep Killestein, MD, PhD, Department of Neurology, VU University Medical Center;
Carlos Nos, MD, Vall d’Hebron Hospital Universitari, 08035;
Francesco Patti, MD, PhD, University of Catania;
Ludo Vanopdenbosch, MD, AZ Sint-Jan Brugge-Oostende;
Timothy Vollmer, MD, Department of Neurology, University of Colorado School of Medicine;
Regine Buffels, MD, F. Hoffmann-La Roche Ltd;
Karen Kadner, MD, PhD, F. Hoffmann-La Roche Ltd;
Thomas Kuenzel, PhD, F. Hoffmann-La Roche Ltd;
Hans-Peter Hartung, M.D., Medical University of Vienna, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Düsseldorf, Brain and Mind Centre, University of Sydney
Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab
Anne H. Cross, MD, Washington University School of Medicine;
Silvia Delgado, MD, University of Miami Miller School of Medicine;
Mario Habek, MD, University Hospital Center Zagreb, University of Zagreb, School of Medicine;
Maria Davydovskaya, PhD, Pirogov Russian National Research Medical University;
Natalia Totolyan, MD, National Medical University;
Ratnakar Pingili, MBBS, Novartis Pharmaceuticals Corporation;
Linda Mancione, BA, Novartis Pharmaceuticals Corporation;
Roseanne Sullivan, PharmD, Novartis Pharmaceuticals Corporation;
Martin Zalesak, MD, PhD, Novartis Pharma AG;
Wendy Su, PhD, TG Therapeutics, Inc;
Krishnan Ramanathan, PhD, Novartis Pharma AG;
Xavier Montalban, MD, PhD, Vall d'Hebron University Hospital;
Kevin Winthrop, MD MPH, School of Public Health at Oregon Health & Science University
Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for Neuromyelitis Optica Spectrum Disorder
Benjamin Greenberg, MD, University of Texas Southwestern;
Dewei She, Ph.D., Viela Bio;
Eliezer Katz, M.D., Viela Bio;
Bruce A.C. Cree, MD, PhD, MAS, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco
Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years
Bruce A.C. Cree, MD, PhD, MAS, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco;
Gavin Giovannoni, MD, PhD, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London;
Ralf Gold, MD, Department of Neurology, St Josef-Hospital, Ruhr-University Bochum;
Robert J. Fox, MD, Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic;
Patrick Vermersch, MD, PhD, Univ. Lille, Inserm U1172, CHU Lille, FHU Precise;
Ralph H.B. Benedict, PhD, University at Buffalo;
Amit Bar-Or, MD, Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania;
Nicolas Rouyrre, MSc, Novartis Pharma AG;
Daniela Piani-Meier, PhD, Novartis Pharma AG;
Shannon Ritter, MS, Novartis Pharmaceuticals Corporation;
Ajay Kilaru, MBBS, Novartis Pharma AG;
Frank Dahlke, MD, Novartis Pharma AG;
Goeril Karlsson, PhD, Novartis Pharma AG;
Ludwig Kappos, MD, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel
Effect of Age on the Change of Lymphocytes and Immunoglobulins during Treatment with Ocrelizumab or Rituximab for Multiple Sclerosis and Related Disorders
Calin Dumitrescu, Medical Student Scholar, Medical College of Wisconsin;
Amber Salter, PhD, Washington University in St. Louis;
Michelle Maynard, PharmD, BCPS, Froedtert and the Medical College of Wisconsin;
Ahmed Z Obeidat, MD, PhD, Medical College of Wisconsin
Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with Suboptimal Response to Prior Disease-Modifying Therapies: Data from the CASTING Study
Celia Oreja-Guevara, MD, Hospital Clinico San Carlos;
Heinz Wiendl, MD, University of Münster;
Aksel Siva, MD, FEAN, Istanbul University;
Karen Kadner, MD, PhD, F. Hoffmann-La Roche Ltd;
Thomas Kuenzel, PhD, F. Hoffmann-La Roche Ltd;
Regine Buffels, MD, F. Hoffmann-La Roche Ltd;
Patrick Vermersch, PhD, University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Imminent
Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World
Chinmay Deshpande, PhD, BPharm, Novartis Pharmaceuticals Corporation;
Mengru Wang, MS, KMK Consulting, Inc.;
Roshani Shah, MPH, Previously employed by Novartis Pharmaceuticals Corporation;
Yutong Chang, MS, KMK Consulting, Inc.;
Fei Yang, PhD, Novartis Pharmaceuticals Corporation;
Wing Chow, PharmD, MPH, Novartis Pharmaceuticals Corporation;
Gina M Cox, PhD, Novartis Pharmaceuticals Corporation
Characterization of Treatment-Naïve Patients with Multiple Sclerosis Newly Initiating Disease-Modifying Therapy
Daniel Kantor, MD, Schmidt College of Medicine, Florida Atlantic University;
Timothy Pham, MS, Bristol Myers Squibb;
Xiu Chen, PhD, Bristol Myers Squibb;
Mayank Mittal, PhD, Bristol Myers Squibb;
Qian Xia, PhD, Bristol Myers Squibb
Click-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)
Augusto A Miravalle, M.D., Advanced Neurology of Colorado, University of Colorado;
Jacob A Sloane, MD PhD, Harvard Medical School;
Julie Aldridge, MS, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany;
Danielle E Harlow, PhD, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany;
Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care
Long-Term Efficacy and Safety of Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder
Dean Wingerchuk, M.D., Mayo Clinic;
Achim Berthele, MD, Technical University of Munich;
Kazuo Fujihara, MD, Southern TOHOKU Research Institute for Neuroscience (STRINS), Tohoku University, Fukushima Medical University;
Celia Oreja-Guevara, MD, Hospital Universitario Clinico San Carlos;
Ho Jin Kim, MD, PhD, Research Institute and Hospital, National Cancer Center;
Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Johns Hopkins University;
Ichiro Nakashima, MD, PhD, Tohoku Medical and Pharmaceutical University, Tohoku University;
Jacqueline Palace, DM, John Radcliffe Hospital;
Shulian Shang, PhD, Alexion Pharmaceuticals;
Marcus Yountz, MD, Alexion Pharmaceuticals;
Larisa Miller, PharmD, Alexion Pharmaceuticals;
Sean J Pittock, M.D., Mayo Clinic
Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies
Denise R. Bruen, MSN, University of Virginia Neuroscience;
Meghan Garabedian, CRNP, MSN, MSCN, Penn Neuroscience Center, Perelmen Center for Advanced Medicine;
Cortnee Roman, MSN, FNP-BC, Rocky Mountain Multiple Sclerosis Clinic and Research Group;
Nicholas W. Robinson, MA, Spherix Global Insights;
Virginia R. Schobel, MSc, Spherix Global Insights;
Jason P. Mendoza, PhD, Biogen;
James B. Lewin, PharmD, Biogen;
Mary Zhang, PharmD, Biogen;
Sai L. Shankar, PhD, Biogen
Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS
Douglas L. Arnold, MD, Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University;
James K. Sheffield, MD, MBA, MS, Bristol Myers Squibb;
Xavier Montalban, MD, PhD, Hospital Universitario Vall d'Hebron;
Bruce A.C. Cree, MD, PhD, MAS, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco;
Ludwig Kappos, MD, Mellen Centre for Multiple Sclerosis;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Hans-Peter Hartung, M.D., Heinrich-Heine-University Düsseldorf, Medical University of Vienna, Brain and Mind Centre, University of Sydney;
Hongjuan Liu, MD, Bristol Myers Squibb;
Chahin Pachai, PhD, Bristol Myers Squibb;
Diego Silva, MD, Bristol Myers Squibb;
Jeffrey A Cohen, MD, Cleveland Clinic Mellen Center
Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Four Data
Elizabeth A Douglas, MPH, The Elliot Lewis Center for Multiple Sclerosis Care;
Rosie M Jungquist, B.S., The Elliot Lewis Center for Multiple Sclerosis Care;
Andrew J Bouley, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Ellen S Lathi, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care
Acapella: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Four Data
Elizabeth A Douglas, MPH, The Elliot Lewis Center for Multiple Sclerosis Care;
Rosie M Jungquist, B.S., The Elliot Lewis Center for Multiple Sclerosis Care;
Andrew J Bouley, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Ellen S Lathi, M.D., The Elliot Lewis Center for Multiple Sclerosis Care
Real-World Cost of Care, Treatment Completion and Site of Care Cost for Patients with Multiple Sclerosis Initiating Infused Disease-Modifying Therapies
Enrique Alvarez, MD, PhD, MSCI, Rocky Mountain Multiple Sclerosis Center at the University of Colorado;
Kavita V Nair, PhD, Rocky Mountain Multiple Sclerosis Center at the University of Colorado;
Hiangkiat Tan, MS, HealthCore Inc.;
Kapil Rathi, PhD, HealthCore Inc.;
Nicole Gabler, PhD, HealthCore Inc.;
Chinmay Deshpande, PhD, BPharm, Novartis Pharmaceuticals Corporation
Real-Life Experience with Ocrelizumab in Older Patients at an Academic MS Center
Evan Luxenberg, MD, University of Washington;
Gloria von Geldern, MD, University of Washington, University of Washington MS Center;
Meghan C Romba, MD, University of Washington MS Center, University of Washington;
Yujie Wang, MD, University of Washington, University of Washington MS Center;
Deborah Gallaro, R.Ph., University of Washington MS Center;
Bren Hammond, RN, BSN, MSCN, University of Washington MS Center;
Jennie Toro, RN, University of Washington MS Center;
Wendy Durand, RN, BSN, University of Washington MS Center;
Melissa F Kennedy, RN, C-MSCN, University of Washington MS Center;
Samantha Kelly, RN, University of Washington MS Center;
Sarika Vyasarayani, RN, BSN, University of Washington MS Center;
Annette Wundes, MD, University of Washington, University of Washington MS Center
Multiple Sclerosis Disease Modifying Therapies’ Adherence and Total Medical Costs Among Women with Maternity Services Using Administrative Data.
Francis C Staskon, PhD, MS, Walgreen, Co.;
Heather Kirkham, PhD, MPH, Walgreen, Co.;
Kathleen Love, RN, BA, AllianceRx Walgreens Prime
Adherence to Multiple Sclerosis Disease Modifying Therapies Using Pharmacy Quality Alliance Criteria and Medical Costs or Hospitalizations in an Administrative Database.
Francis C Staskon, PhD, MS, Walgreen, Co.;
Heather Kirkham, PhD, MPH, Walgreen, Co.;
Kathleen Love, RN, BA, AllianceRx Walgreens Prime
Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study
Heinz Wiendl, MD, University of Münster;
Klaus Schmierer, MD, PhD, Queen Mary University of London;
Suzanne Hodgkinson, MD, UNSW Medicine;
Tobias Derfuss, MD, Departments of Medicine and Biomedicine, University Hospital and University of Basel;
Andrew Chan, MD, Inselspital;
Finn Sellebjerg, MD, University of Texas Southwestern Medical Center;
Anat Achiron, MD, PhD, Sheba Medical Center;
Xavier Montalban, MD, PhD, St Michael’s Hospital, University of Toronto;
Alexandre Prat, MD, Université de Montréal;
Nicola De Stefano, MD, PhD, University of Siena;
Frederik Barkhof, MD, PhD, Institutes of Neurology and Healthcare Engineering, University College London, VU University Medical Center;
Letizia Leocani, MD, Ospedale San Raffaele;
Patrick Vermersch, PhD, University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Imminent;
Anita Chudecka, MA, Cytel, Inc.;
Sanjeev Roy, MD, Merck KGaA, Darmstadt, Germany;
Ursula Boschert, PhD, Merck KGaA, Darmstadt, Germany
Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 Experience–US Study
Jacob A Sloane, MD PhD, Beth Israel Deaconess Medical Center;
Kyle E. Smoot, MD, Providence Multiple Sclerosis Center, Providence Brain and Spine Institute;
Bianca Weinstock-Guttman, MD, Jacobs Multiple Sclerosis Center for Treatment and Research, Jacobs School of Medicine and Biomedical Science, University at Buffalo;
Sibyl Wray, MD, Hope Neurology;
Miguel Rosales, MSc, Biogen;
Sai L. Shankar, PhD, Biogen;
Justin Bohn, ScD, Biogen;
Catherine Miller, PharmD, MPH, Biogen;
Jordan Messer, PharmD, Biogen;
Jason P. Mendoza, PhD, Biogen;
James B. Lewin, PharmD, Biogen
COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths
Jakai Nolan, DO, MPH, OhioHealth;
Jacqueline Nicholas, MD, MPH, OhioHealth;
Andrew Smith, MD, OhioHealth;
Irene Koulinska, MD, ScD, Biogen;
Arman Altincatal, MS, Biogen;
Cyndi Grossman, PhD, Biogen;
Scott Husak, Statistical Programmer, Cleveland Clinic;
Kedar Mahajan, MD, PhD, Cleveland Clinic;
Robert A Bermel, MD, Mellen Center for MS, Cleveland Clinic;
Jeff Cohen, MD, Cleveland Clinic;
Brandon Moss, MD, Cleveland Clinic
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19
Gavin Giovannoni, MD, PhD, Queen Mary University of London;
Joseph Berger, MD, FACP, FAAN, FANA, Perelman School of Medicine, University of Pennsylvania;
Thomas P. Leist, MD, Division of Clinical Neuroimmunology, Jefferson University;
Dominic Jack, PhD, Merck KGaA;
Andrew Galazka, MD, Merck KGaA, Darmstadt, Germany;
Axel Nolting, MD, Merck KGaA, Darmstadt, Germany;
Doris Damian, PhD, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany
Natalizumab: Management and Safety during the COVID-19 Pandemic
Judit Díaz-Díaz, MD, University Hospital Clinico San Carlos, IdiSSC;
Clara Isabel Ramirez, MD, University Hospital Clinico San Carlos, IdiSSC;
Marta Ortiz-Pica, Nurse, University Hospital Clinico San Carlos;
Irene Gómez-Estevez, MD, University Hospital Clinico San Carlos, IdiSSC;
Elena García Yusta, Nurse, University Hospital Clinico San Carlos;
Celia Oreja-Guevara, MD, University Hospital Clinico San Carlos, IdiSSC
Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a
Kathryn C Fitzgerald, ScD, Johns Hopkins Medicine, Department of Neurology;
Carrie M Hersh, DO, MS, Cleveland Clinic, Lou Ruvo Center for Brain Health;
Lana Zhovtis Ryerson, MD, NYU Grossman School of Medicine, Department of Neurology;
Ellen M Mowry, MD, MCR, Johns Hopkins University School of Medicine;
Shirley Liao, PhD, Biogen;
Arman Altincatal, MS, Biogen;
Maria L Naylor, PhD, Biogen
Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem
Krupa Pandey, MD, Hackensack University Medical Center;
Kathryn Giles, MD, MSc, FRCPC, Cambridge Memorial Hospital;
Konstantin Balashov, MD, PhD, Boston Medical Center and Boston University;
Richard Macdonell, MD, Austin Health, University of Melbourne;
Jörg Windsheimer, MD, Praxis fur Neurologie und Psychiatrie;
Annette F Okai, MD, Multiple Sclerosis Treatment Center of Dallas;
Mikel Martinez, MD, Centre Hospitalier Dax;
Oksana Mokliatchouk, PhD, Biogen;
Jennifer Lyons, MD, Biogen;
Shivani Kapadia, PharmD, RPh, Biogen;
Nicholas J Everage, PhD, Biogen
Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study
Le H. Hua, MD, Lou Ruvo Center for Brain Health;
Amit Bar-Or, MD, Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania;
Fred D. Lublin, MD, Icahn School of Medicine at Mount Sinai;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Gina Mavrikis Cox, PhD, Novartis Pharmaceuticals Corporation;
Bruce A.C. Cree, MD, PhD, MAS, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco;
Robert J. Fox, MD, Cleveland Clinic
Assessing the Impact of Fingolimod Adherence on Relapse and Costs Using Marginal Structural Models
Le H. Hua, MD, Lou Ruvo Center for Brain Health;
Roshani Shah, MS, Novartis Pharmaceuticals Corporation;
Gina Mavrikis Cox, PhD, Novartis Pharmaceuticals Corporation;
Tim Bancroft, PhD, Optum;
Rachel Halpern, PhD, Optum;
Miriam G. Cisternas, MA, Optum
Olikos Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients Who Transition from Intravenous Anti-CD20 Therapy
Le H Hua, MD, Cleveland Clinic Lou Ruvo Center for Brain Health;
Enrique Alvarez, MD, PhD, MSCI, University of Colorado;
Roland G Henry, PhD, Weill Institute for Neurosciences;
Joel Brown, PhD, PharmD, Novartis Pharmaceuticals Corporation;
Elizabeth Camacho, MBA, Novartis Pharmaceuticals Corporation;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Marina Ziehn, PhD, Novartis Pharma AG;
Brandon Brown, PharmD, Novartis Pharmaceuticals Corporation;
Benjamin M Greenberg, MD, MHS, UT Southwestern Medical Center
Incidence and Severity of Natalizumab Infusion-Related Reactions during Infusion and Postinfusion Observation
Ling Jin, MD, Biogen;
Zheng Ren, PhD, Biogen;
Prabjot Hunjan, BSc, PgDip, Biogen;
Seth Levin, MD, Biogen;
Stephanie Licata, PhD, Biogen
Dual Mode of Action of Siponimod in Secondary Progressive Multiple Sclerosis: A Hypothesis Based on the Relevance of Pharmacological Properties
Marc Bigaud, PhD, Novartis Pharma AG;
Frank Dahlke, MD, Novartis Pharma AG;
Thomas Hach, MD, Novartis Pharma AG;
Daniela Piani-Meier, PhD, Novartis Pharma AG;
Ralf Gold, MD, Department of Neurology, St Josef-Hospital, Ruhr-University Bochum
Post-Approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC, University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute;
Hans Guehring, MD, Merck KGaA;
Zuzana Murgasova, MD, Merck KGaA;
Dominic Jack, PhD, Merck KGaA
Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data
Mark Gudesblatt, MD, South Shore Neurologic Associates;
Myassar Zarif, MD, South Shore Neurologic Associates;
Barbara Bumstead, MS, ANP-C, MSCN, South Shore Neurologic Associates;
Marijean Buhse, NP-C, PhD, South Shore Neurologic Associates;
Olivia Kaczmarek, BS, South Shore Neurologic Associates;
Jared Srinivasan, BS, Biogen;
Nuno Barros, PhD, icometrix;
Annemie Ribbens, PhD, icometrix;
Wim Van Hecke, PhD, icometrix;
Elise Digga, BA, Icahn School of Medicine at Mt. Sinai;
Jason P. Mendoza, PhD, Biogen;
Stephen Krieger, MD, Icahn School of Medicine at Mt. Sinai
Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent
Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Johns Hopkins University;
Achim Berthele, MD, Technical University of Munich;
Ho Jin Kim, MD, PhD, Research Institute and Hospital, National Cancer Center;
Kazuo Fujihara, MD, Southern TOHOKU Research Institute for Neuroscience (STRINS), Tohoku University, Fukushima Medical University;
Ichiro Nakashima, MD, PhD, Tohoku Medical and Pharmaceutical University, Tohoku University;
Celia Oreja-Guevara, MD, Hospital Universitario Clinico San Carlos;
Jacqueline Palace, DM, John Radcliffe Hospital;
Sean J Pittock, M.D., Mayo Clinic;
Murat Terzi, MD, Ondokuz Mayis University;
Natalia Totolyan, MD, National Medical University;
Shanthi Viswanathan, MRCP, Kuala Lumpur Hospital;
Kai-Chen Wang, MD, PhD, National Yang Ming University, Cheng-Hsin General Hospital;
Amy Pace, ScD, Alexion Pharmaceuticals;
Marcus Yountz, MD, Alexion Pharmaceuticals;
Diane Lawson, PharmD, RPh, Alexion Pharmaceuticals;
Eva Laudon-Meyer, MD PhD, Alexion Pharmaceuticals;
Dean Wingerchuk, M.D., Mayo Clinic
Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening – Early 3 Months Post Approval Data
Mitzi J Williams, MD, Joi Life Wellness Group, LLC;
Janine Robinson, MS, W2O Group;
Katarzyna Elliott-Maksymowicz, MSc, W2O Group;
Bianca Luscher, BS, W2O Group;
Chinmay Deshpande, PhD, BPharm, Novartis Pharmaceuticals Corporation
Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
Mokshal H Porwal, BSc, Medical College of Wisconsin;
Dhruvkumar Patel, BMSc, Arizona College of Osteopathic Medicine;
Michelle Maynard, PharmD, BCPS, Froedtert and the Medical College of Wisconsin;
Ahmed Z Obeidat, MD, PhD, Medical College of Wisconsin
Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans
Nicole Tsao, PhD, Biogen;
Shaobin Dong, MBA, Biogen;
Maria L Naylor, PhD, Biogen;
Qiang Hou, PhD, Biogen;
Mandakini Awasthy, MS, Biogen
Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data
Patricia K. Coyle, MD, Department of Neurology, Stony Brook University;
Magdaliz Gorritz, MPH, IQVIA;
Rolin L Wade, RPh, MS, IQVIA;
Zifan Zhou, MS, IQVIA;
Yao Cao, MS, IQVIA;
Chinmay Deshpande, PhD, BPharm, Novartis Pharmaceuticals Corporation
Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study
Ralph H.B. Benedict, PhD, University at Buffalo;
Iris-Katharina Penner, PhD, Heinrich Heine University, COGITO Center for Applied Neurocognition and Neuropsychological Research;
Ludwig Kappos, MD, Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel;
Patrick Vermersch, MD, PhD, Univ. Lille, Inserm UMR U1172 LilNCog, CHU Lille;
Bruce A.C. Cree, MD, PhD, MAS, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco;
Ralf Gold, MD, Department of Neurology, St Josef-Hospital, Ruhr-University Bochum;
Amit Bar-Or, MD, Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania;
Daniela Piani-Meier, PhD, Novartis Pharma AG;
Shannon Ritter, MS, Novartis Pharma AG;
Sophie Arnould, MSc, Novartis Pharma AG;
Goeril Karlsson, PhD, Novartis Pharma AG;
Frank Dahlke, MD, Novartis Pharma AG;
Thomas Hach, MD, Novartis Pharma AG;
Robert J. Fox, MD, Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic;
Douglas L. Arnold, MD, NeuroRx Research, Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University
Safety of Eculizumab in Nmosd and MG – Analysis of the Phase 3 Studies Prevent and Regain and Their Extensions
Renato Mantegazza, MD, Fondazione IRCCS, Istituto Neurologico Carlo Besta;
Todd Levine, MD, Phoenix Neurological Associates;
Celia Oreja-Guevara, MD, Hospital Universitario Clinico San Carlos;
Cynthia Carrillo-Infante, MD, Alexion Pharmaceuticals;
Eva Laudon-Meyer, MD PhD, Alexion Pharmaceuticals;
Shulian Shang, PhD, Alexion Pharmaceuticals;
Sean J Pittock, M.D., Mayo Clinic;
James F. Howard Jr., MD, University of North Carolina
Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years
Douglas L. Arnold, MD, NeuroRx Research, Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University;
Ludwig Kappos, MD, Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel;
Patrick Vermersch, MD, PhD, Univ. Lille, Inserm UMR U1172 LilNCog, CHU Lille;
Ralf Gold, MD, Department of Neurology, St Josef-Hospital, Ruhr-University Bochum;
Amit Bar-Or, MD, Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania;
Gavin Giovannoni, MD, PhD, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London;
Bruce A.C. Cree, MD, PhD, MAS, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco;
Daniela Piani-Meier, PhD, Novartis Pharma AG;
Shannon Ritter, MS, Novartis Pharmaceuticals Corporation;
Goeril Karlsson, PhD, Novartis Pharma AG;
Frank Dahlke, MD, Novartis Pharma AG;
Thomas Hach, MD, Novartis Pharma AG;
Robert J. Fox, MD, Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic
Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis
Robert T. Naismith, MD, Washington University School of Medicine;
Jeffrey A Cohen, MD, Cleveland Clinic Mellen Center;
Amit Bar-Or, MD, Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Krzysztof Selmaj, MD, Center for Neurology;
Hans-Peter Hartung, M.D., Heinrich-Heine-University Düsseldorf;
James K. Sheffield, MD, MBA, MS, Bristol Myers Squibb;
Neil Minton, MD FFPM, Bristol Myers Squibb;
Marc Gleichmann, MD, Bristol Myers Squibb;
Hongjuan Liu, MD, Bristol Myers Squibb;
Jon V Riolo, PhD, Bristol Myers Squibb;
Diego Silva, MD, Bristol Myers Squibb;
Bruce A.C. Cree, MD, PhD, MAS, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco
Is There ‘Wearing Off’ with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).
Rose-Marie M Jungquist, B.S., The Elliot Lewis Center for Multiple Sclerosis Care;
Martin Malik, B.S., NYU Langone Health;
Zoe Rimler, B.S., NYU Langone Health;
Elizabeth A Douglas, MPH, The Elliot Lewis Center for Multiple Sclerosis Care;
Andrew J Bouley, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Ellen S Lathi, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Ilya Kister, MD, Barnabas Health Medical Group
Acapella: B-Cell Repletion in Ocrelizumab-Treated Patients
Rosie M Jungquist, B.S., The Elliot Lewis Center for Multiple Sclerosis Care;
Elizabeth A Douglas, MPH, The Elliot Lewis Center for Multiple Sclerosis Care;
Andrew J Bouley, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Ellen S Lathi, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care
Clinical Outcomes in Patients with COVID-19 Infection during Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis
Radmila Karan, MD, Merck KGaA, Darmstadt, Germany;
Sanjeev Roy, MD, Merck KGaA, Darmstadt, Germany;
Nektaria Alexandri, MD, MSc, Merck KGaA, Darmstadt, Germany
Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder
Sean J Pittock, M.D., Mayo Clinic;
Kazuo Fujihara, MD, Southern TOHOKU Research Institute for Neuroscience (STRINS), Tohoku University, Fukushima Medical University;
Jacqueline Palace, DM, John Radcliffe Hospital;
Achim Berthele, MD, Technical University of Munich;
Ho Jin Kim, MD, PhD, Research Institute and Hospital, National Cancer Center;
Celia Oreja-Guevara, MD, Hospital Universitario Clinico San Carlos;
Ichiro Nakashima, MD, PhD, Tohoku University, Tohoku Medical and Pharmaceutical University;
Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Johns Hopkins University;
Shulian Shang, PhD, Alexion Pharmaceuticals;
Marcus Yountz, MD, Alexion Pharmaceuticals;
Larisa Miller, PharmD, Alexion Pharmaceuticals;
Roisin Armstrong, PhD, Alexion Pharmaceuticals;
Dean Wingerchuk, M.D., Mayo Clinic
Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis
Sibyl Wray, MD, Hope Neurology MS Center;
Marco Salvetti, MD, Sapienza University, S. Andrea Hospital;
Gereon Nelles, MD, Neurology, NeuroMed Campus Hohenlind;
Arman Altincatal, MS, Biogen;
Nydjie Grimes, MPH, BA, Biogen;
Achint Kumar, MBBS, MD, Biogen;
Maria L Naylor, PhD, Biogen
Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the Asclepios I/II and Apolitos Studies
Silvia Delgado, MD, University of Miami Miller School of Medicine;
Mitzi J Williams, MD, Joi Life Wellness MS Center;
Morten Bagger, PhD, Novartis Pharma AG;
Gordon Graham, PhD, Novartis Pharma AG;
Etienne Pigeolet, PhD, Novartis Pharma AG;
Huixin Yu, PhD, Novartis Pharma AG;
Dieter A. Haering, PhD, Novartis Pharma AG;
Roman Willi, PhD, Novartis Pharma AG;
Cecile Kerloeguen, MSc, Novartis Pharma AG;
Chao Xu, PhD, China Novartis Institute of Biomedical Research;
Masaru Hirano, PhD, Novartis Pharmaceutics, K.K.;
Dee Stoneman, MPharm, Novartis Pharma AG;
Wendy Su, PhD, TG Therapeutics, Inc;
Krishnan Ramanathan, PhD, Novartis Pharma AG;
Jin Nakahara, MD, PhD, Keio University School of Medicine
Pregnancy Outcomes in the Ozanimod Clinical Development Program in Relapsing Multiple Sclerosis, Ulcerative Colitis, and Crohn’s Disease
Sonia Afsari, MD, Bristol Myers Squibb;
Alyssa Henry, MD, Bristol Myers Squibb;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Marla C. Dubinsky, MD, Icahn School of Medicine;
Uma Mahadevan, MD, University of California San Francisco;
Lorna Charles, MD, Bristol Myers Squibb;
C. Janneke van der Woude, MD, PhD, Erasmus MC;
Krzysztof Selmaj, MD, Center for Neurology
Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study
Stanley Cohan, MD, PhD, Providence Brain and Spine Institute, and Providence Multiple Sclerosis Center, Providence Health & Services;
Le H. Hua, MD, Lou Ruvo Center for Brain Health;
Amit Bar-Or, MD, Department of Neurology, Perelman School of Medicine, University of Pennsylvania;
Fred D. Lublin, MD, Icahn School of Medicine at Mount Sinai;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Gina Mavrikis Cox, PhD, Novartis Pharmaceuticals Corporation;
Patricia K. Coyle, MD, Multiple Sclerosis Comprehensive Care Center, Stony Brook University;
Robert J. Fox, MD, Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic
Classic-MS: Long-Term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis Who Received Cladribine Tablets in Phase III Parent Trials
Gavin Giovannoni, MD, PhD, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London;
Aida Aydemir, MSc, EMD Serono Research & Development Institute Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany;
Elisabetta Verdun di Cantogno, MD, PhD, Merck KGaA;
Thomas P. Leist, MD, Division of Clinical Neuroimmunology, Jefferson University
Does Frequency and Severity of COVID-19 Differ By Disease Modifying Therapy in MS Patients?
Tyler E Smith, M.D., NYU Langone Health;
Maya Madhavan, M.D., NYU Langone Health;
Daniel Gratch, M.D., NYU Langone Health;
Aneek Patel, B.S., NYU School of Medicine;
Valerie Saha, NP, NYU Langone Health;
Carrie Sammarco, DrNP, NYU Langone Health;
Zoe Rimler, B.S., NYU Langone Health;
Guadalupe Zuniga, ., NYU Langone Health;
Dunia Gragui, ., NYU Langone Health;
Leigh E Charvet, PhD, NYU Langone Health;
Gary Cutter, PhD, University of Alabama at Birmingham;
Lauren Krupp, MD, NYU Langone Health;
Ilya Kister, MD, NYU Langone Health;
Lana Zhovtis Ryerson, M.D., NYU Langone Health
Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study
Xavier Montalban, MD, PhD, Vall d'Hebron University Hospital;
Douglas L. Arnold, MD, McGill University;
Martin S Weber, MD, Universitie Göttingen;
Ivan Staikov, MD, PhD, Acibadem City Clinic Tokuda Hospital;
Karolina Piasecka-Stryczynska, PhD, Poznan University of Medical Sciences;
Emily C. Martin, PhD, EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany;
Matthew Mandel, MD, EMD Serono Research & Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt, Germany);
Yulia Zima, PhD, EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany;
Jamie Shaw, BS, EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany;
Fernando Dangond, MD, MBA, EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany;
Roland Grenningloh, MD, EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany;
Ying Li, MS, Global Clinical Development Center;
Davorka Tomic, DVm, MSc, PhD, Merck KGaA;
Jerry S Wolinsky, MD, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth)
Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing Forms of Multiple Sclerosis: Interim Analysis
Tarun Singhal, MD, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Kelsey Carter, BS, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
John Hunter Ficke, BA, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Preksha Kukreja, BS, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Eero Rissanen, MD, PhD, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Gauruv Bose, MD, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Bonnie Glanz, PhD, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Jonathan Zurawski, MD, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Steven Cicero, BS, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Maria Houtchens, MD, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Christopher A Severson, MD, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Shipra Dubey, PhD, Nuclear Medicine Division, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School;
Bo Yeun Yang, PhD, Nuclear Medicine Division, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School;
Brandon Brown, PharmD, Novartis Pharmaceuticals Corporation;
Rohit Bakshi, MD, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Harald Kropshofer, PhD, Novartis Pharma AG;
Tanuja Chitnis, MD, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Howard L Weiner, MD, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School;
Marina Ziehn, PhD, Novartis Pharma AG
Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls
Timothy Vollmer, MD, Rocky Mountain MS Center;
Daniel Pelletier, MD, Multiple Sclerosis Comprehensive Care Center At USC;
Sibyl Wray, MD, Hope Neurology;
Barry Hendin, MD, Center for Neurology and Spine;
Linda-Ali Cruz, MD, Novartis Pharmaceuticals Corporation;
James Stankiewicz, MD, Novartis Pharmaceuticals Corporation;
Ratnakar Pingili, MBBS, Novartis Pharmaceuticals Corporation;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Andy Cheadle, PhD, Novartis Pharmaceuticals Corporation;
Jeffrey A Cohen, MD, Cleveland Clinic Mellen Center
